Efficacy of Guanfacine Extended Release in the Treatment of Combined and Inattentive Only Subtypes of Attention-Deficit/Hyperactivity Disorder
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Extended-release guanfacine (GXR) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness. METHOD: Data from two large double-blind placebo-controlled pivotal trials of GXR in the treatment of ADHD were analyzed. Using the pooled population to provide sufficient sample size and associated statistical power, the impact of GXR treatment on core ADHD symptoms was examined by comparing ADHD Rating Scale IV (ADHD-RS-IV) total scores in the overall GXR and placebo groups in subjects with each of the three ADHD subtypes. ADHD-RS-IV Hyperactivity-Impulsivity and Inattentiveness subscale scores in the overall study population by randomized dose group (vs. placebo) were also examined. RESULTS: The full analysis set included 631 subjects aged 6-17 years (GXR: n=490; placebo: n=141). Among subjects with the predominantly inattentive subtype of ADHD, differences in least squares (LS) mean reductions from baseline in ADHD-RS-IV total scores were significantly greater in GXR-treated subjects (n=127) than in placebo-treated subjects (n=38) at treatment weeks 3 through 5 and end point (p≤0.020). Among subjects with combined type ADHD, differences in LS mean ADHD-RS-IV total score reductions from baseline were significantly greater in the GXR group (n=354) than in the placebo group (n=100) at treatment weeks 1 through 5 and end point (p≤0.011). The dearth of predominantly hyperactive-impulsive type subjects (n=12) precluded analysis of this subgroup. Each randomized GXR dose group in each trial demonstrated significantly greater reductions from baseline in ADHD-RS-IV Hyperactivity-Impulsivity and Inattentiveness subscale scores than did the respective placebo group at end point (p≤0.05 for all). CONCLUSIONS: The results support the use of GXR in the treatment of core ADHD symptoms as defined in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision, including hyperactivity, impulsivity, and inattention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
ADHD combined type and ADHD predominantly inattentive type are distinct and unrelated disorders.
Milich, R., Balentine, A. C., & Lynam, D. R. (2001) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy.8.4.463 · Cited by 647 · cited 1×
“At the other end of the spectrum, researchers have proposed that the combined and inattentive subtypes of ADHD may be distinct unrelated disorders (Lahey 2001; Milich et al. 2001; Solanto et al. 2007).”
Instability of the DSM-IV Subtypes of ADHD From Preschool Through Elementary School
Lahey, B. B., Pelham, W. E., Loney, J., Lee, S. S., & Willcutt, E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.8.896 · Cited by 528
A Comparison of the Neuropsychological Profiles of the DSM-IV Subtypes of ADHD
Chhabildas, N., Pennington, B. F., & Willcutt, E. G. (2001) · Journal of Abnormal Child Psychology · doi:10.1023/a:1012281226028 · Cited by 461
Sallee, F. R., Mcgough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318191769e · Cited by 391
Self-citationBiederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317 · cited 12×
“(Biederman et al. 2008; Sallee et al. 2009).”
InfluentialTesting Structural Models of DSM-IV Symptoms of Common Forms of Child and Adolescent Psychopathology
Lahey, B. B., Rathouz, P. J., Van Hulle, C., Urbano, R. C., Krueger, R. F., Applegate, B., Garriock, H. A., Chapman, D. A., & Waldman, I. D. (2008) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-007-9169-5 · Cited by 286
Neurocognitive Functioning in AD/HD, Predominantly Inattentive and Combined Subtypes
Solanto, M. V., Gilbert, S. N., Raj, A., Zhu, J., Pope-Boyd, S., Stepak, B., Vail, L., & Newcorn, J. H. (2007) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-007-9123-6 · Cited by 195 · cited 2×
“At the other end of the spectrum, researchers have proposed that the combined and inattentive subtypes of ADHD may be distinct unrelated disorders (Lahey 2001; Milich et al. 2001; Solanto et al. 2007).”
Remission versus response as the goal of therapy in ADHD: A new standard for the field?
Steele, M., Jensen, P. S., & Quinn, D. M. P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.006 · Cited by 174 · cited 2×
“GXR to reduce symptoms of inattention is also highlighted by the fact that most subjects with predominantly inattentive ADHD receiving treatment with GXR had end point ADHD-RS-IV total scores < 18 (median = 15), a cutoff frequently used to define remission (Steele et al. 2006).”
Jain, R., Segal, S., Kollins, S. H., & Khayrallah, M. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.11.005 · Cited by 142 · cited 1×
“…in the current report is within the range of dropout rates observed for a similar short-term study of extended-release clonidine for treating ADHD in children and adolescents (Jain et al. 2011), and is also consistent with some trials of amphetamine for treating adult ADHD (Castells et al. 2011).”
Self-citation
Cited by
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Hirota, T., Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.009 · Cited by 161
Fox, H., Sofuoglu, M., & Sinha, R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114562464 · Cited by 30
“In support, guanfacine has been shown to be particularly robust in treating conditions characterized by catecholaminergic psychopathology including symptoms of attention-deficit hyperactivity disorder (ADHD) (Chappell et al., 1995; Childress, 2012; Hunt et al., 1995; Sallee et al., 2012; Scahill et al., 2001), age-rel…”
Kawaura, K., Karasawa, J.-I., Chaki, S., & Hikichi, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.044 · Cited by 29
Metadata
- Authors
- Sallee, F. R., Kollins, S. H., & Wigal, T. L.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-06
- Volume
- 22
- Issue
- 3
- Pages
- 206-214
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2059249474
- Cited by
- 33
- References
- 13
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.